Skip to content

Platelet rich plasma (PRP) role in the treatment of baldness

Role of platelet rich plasma (PRP) in the treatment of male type baldness

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/05/014113
Enrollment
80
Registered
2018-05-25
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Male type baldness

Interventions

Intervention1: Platelet Rich Plasma: subcutaneous injection of platelet rich plasma monthly for three sitting over whole scalp followed by 3 month follow up platelet rich plasma prepared from patient

Sponsors

Institute of Medical sciences Banaras Hindu University
Lead Sponsor
Dr Tulika Rai
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: 1. All the patients not using topical minoxidil and finasteride for at least 6 months will be considered for PRP therapy. 2. Age group 20 â?? 60 years 3. Sex- Male 4. Mild to moderate AGA (Hamilton-Norwood score II-V) . 5. Patients willing to come for follow up every month for 5 months.

Exclusion criteria

Exclusion criteria: 1. Patients not giving informed written consent, unable to understand the protocol and uncooperative patients. 2. Any inflammation, erythema or scarring over scalp except mild seborrheic dermatitis. 3. Patients who have history of malignancies, platelets disorders or bleeding disorders, anemia ( haemoglobulin of less than 10 gm/dl), bone marrow aplasia, diabetes, sepsis, and cancer. 4. Patients taking theses any of these medications- i. Anti-coagulants â?? heparin, warfarin ii. Anti-hypertensives â?? beta-blockers, ACE inhibitors hormones iii. Anticonvulsants â?? valproic acid, carbamazepine, phenytoin, mood stabilizers Antidepressants, lithium iv. Aspirin or any non-steroidal anti-inflammatory drugs two week prior to procedure. v. Other medications cimetidine, retinoids (acitretin > isotretinoin), antithyroid drugs, cholesterol lowering drugs, interferons, amphetamines, bromocriptine, levodopa, some antipsychotic and anti-anxiety drugs, rarely tricyclic antidepressants such as amitriptyline 5. Patients who are known to be HIV, hepatitis B or C positive or otherwise immunocompromised. 6. Patients with a propensity for keloids 7. Patients on antiplatelet drugs like aspirin or non-steroidal anti-inflammatory drugs.

Design outcomes

Primary

MeasureTime frame
Hair density Hamilton Norwood grading Patient self assessmentTimepoint: every month for 5 months

Secondary

MeasureTime frame
Age sex occupation Education status Family History History of previous treatment for male type baldness Effect on personality Timepoint: Every month for 5 months

Countries

India

Contacts

Public ContactDr Vijay Kumar

Institute of Medical Sciences BHU

drsatyendraderma@gmail.com9198120582

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026